IL2RG and diabetes mellitus: We found that anti-CD132 administration protected NOD mice from diabetes onset, hyperglycemia, and destructive insulitis compared with the isotype control group (Fig. 7b–d), with no difference in body weight (Supplementary Fig. S7a).